Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia.

2.50
Hdl Handle:
http://hdl.handle.net/10033/621278
Title:
Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia.
Authors:
Kumaraswamy, Monika; Lin, Leo; Olson, Joshua; Sun, Ching-Fang; Nonejuie, Poochit; Corriden, Ross; Döhrmann, Simon; Ali, Syed Raza; Amaro, Deirdre; Rohde, Manfred ( 0000-0003-0522-3580 ) ; Pogliano, Joe; Sakoulas, George; Nizet, Victor
Abstract:
The Gram-negative bacillus Stenotrophomonas maltophilia (SM) is an emerging MDR opportunistic pathogen. Recent studies identify a potentially relevant activity of azithromycin against Gram-negative bacteria overlooked in standard bacteriological testing. We investigated azithromycin activity against SM in testing conditions incorporating mammalian tissue culture medium and host defence factors.
Affiliation:
Helmholtz-Zentrum für Infectionsforschung GmbH, Inhoffenstr.7, 38124 Braunschweig, Germany.
Citation:
Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia. 2016, 71 (5):1264-9 J. Antimicrob. Chemother.
Journal:
The Journal of antimicrobial chemotherapy
Issue Date:
May-2016
URI:
http://hdl.handle.net/10033/621278
DOI:
10.1093/jac/dkv487
PubMed ID:
26832758
PubMed Central ID:
PMC4830416
Additional Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830416/
Type:
Article
Language:
en
ISSN:
1460-2091
Appears in Collections:
publications of the central unit for microscopy (ZEIM)

Full metadata record

DC FieldValue Language
dc.contributor.authorKumaraswamy, Monikaen
dc.contributor.authorLin, Leoen
dc.contributor.authorOlson, Joshuaen
dc.contributor.authorSun, Ching-Fangen
dc.contributor.authorNonejuie, Poochiten
dc.contributor.authorCorriden, Rossen
dc.contributor.authorDöhrmann, Simonen
dc.contributor.authorAli, Syed Razaen
dc.contributor.authorAmaro, Deirdreen
dc.contributor.authorRohde, Manfreden
dc.contributor.authorPogliano, Joeen
dc.contributor.authorSakoulas, Georgeen
dc.contributor.authorNizet, Victoren
dc.date.accessioned2018-02-15T08:55:09Z-
dc.date.available2018-02-15T08:55:09Z-
dc.date.issued2016-05-
dc.identifier.citationStandard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia. 2016, 71 (5):1264-9 J. Antimicrob. Chemother.en
dc.identifier.issn1460-2091-
dc.identifier.pmid26832758-
dc.identifier.doi10.1093/jac/dkv487-
dc.identifier.urihttp://hdl.handle.net/10033/621278-
dc.description.abstractThe Gram-negative bacillus Stenotrophomonas maltophilia (SM) is an emerging MDR opportunistic pathogen. Recent studies identify a potentially relevant activity of azithromycin against Gram-negative bacteria overlooked in standard bacteriological testing. We investigated azithromycin activity against SM in testing conditions incorporating mammalian tissue culture medium and host defence factors.en
dc.language.isoenen
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830416/en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAnimalsen
dc.subject.meshAnti-Infective Agentsen
dc.subject.meshAntimicrobial Cationic Peptidesen
dc.subject.meshAzithromycinen
dc.subject.meshColistinen
dc.subject.meshDisease Models, Animalen
dc.subject.meshDrug Synergismen
dc.subject.meshGram-Negative Bacterial Infectionsen
dc.subject.meshHumansen
dc.subject.meshMiceen
dc.subject.meshMicrobial Sensitivity Testsen
dc.subject.meshNeutrophilsen
dc.subject.meshPneumonia, Bacterialen
dc.subject.meshStenotrophomonas maltophiliaen
dc.subject.meshTreatment Outcomeen
dc.titleStandard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia.en
dc.typeArticleen
dc.contributor.departmentHelmholtz-Zentrum für Infectionsforschung GmbH, Inhoffenstr.7, 38124 Braunschweig, Germany.en
dc.identifier.journalThe Journal of antimicrobial chemotherapyen
dc.identifier.pmcidPMC4830416-

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.